Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sorrento Acquires ACEA, a San Diego-China Drug Developer, in $488 Million Deal

publication date: Apr 5, 2021

Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in China. Sorrento will pay $38 million upfront in stock and make up to an additional $450 million in milestones payments. The acquisition will include three ACEA candidates, one in Phase III, another in early clinical stage and a third in preclinical studies, along with ACEA’s library of over one million small molecules. ACEA has a manufacturing facility in China. More details....

Stock Symbol: (NSDQ: SRNE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.